Insight Molecular Diagnostics Business Summary

Insight Molecular Diagnostics Inc. (IMDX), formerly Oncocyte Corporation, is a precision diagnostics firm specializing in oncology and transplant monitoring. The company generates revenue through a dual-stream model: laboratory service fees from its CLIA-certified facility in Nashville and the commercial sale of proprietary molecular diagnostic kits. Its primary business segments include transplant diagnostics—anchored by the GraftAssureDx™ (clinical IVD) and GraftAssureIQ™ (RUO) platforms—and oncology services featuring the DetermaIO™ and DetermaRx™ assays. IMDX is currently executing a strategic pivot from a centralized service model to a decentralized product model, targeting a $1 billion addressable market by enabling transplant centers to perform in-house donor-derived cell-free DNA (dd-cfDNA) testing. Key direct competitors include CareDx, Natera, Guardant Health, and NeoGenomics; IMDX distinguishes itself by offering kitted solutions that reduce turnaround times and costs compared to the centralized laboratory models of its larger peers. The leadership team is led by President and CEO Joshua Riggs, a veteran business strategist who previously founded Intelliger Consulting and held senior roles at Bethesda Group. Chief Financial Officer Andrea James brings significant scaling expertise from her tenure at Axon Enterprise, where she oversaw a market capitalization expansion from $1 billion to over $20 billion. The technical core includes Chief Technology Officer Yuh-Min Chiang, formerly of Alveo Technologies, and Chief Science Officer Dr. Ekkehard Schutz, an expert in molecular genetics who joined via the acquisition of Chronix Biomedical. The company is backed by a strong institutional base, with Broadwood Capital holding a dominant 35% stake alongside Bio-Rad Laboratories and AWM Investment Company. The Board of Directors is chaired by Andrew Arno, a seasoned investment banker with over 30 years of experience in emerging growth biotechnology, who recently oversaw a $26 million registered direct offering in February 2026 to fund the commercial launch of the GraftAssureDx™ platform.